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Abstract
Infection with Coxiella burnetii may lead to life-threatening chronic Q fever endocarditis or vascular infections, which are often difﬁcult to
diagnose. The present study aims to investigate whether measurement of in-vitro interferon-gamma (IFN-c) production, a key cytokine in the
immune response against C. burnetii, differentiates chronic from a past cleared infection, and whether measurement of other cytokines
would improve the discriminative power. First, C. burnetii-speciﬁc IFN-c production was measured in whole blood of 28 deﬁnite chronic Q
fever patients and compared with 135 individuals with past Q fever (seropositive controls) and 908 seronegative controls. IFN-c production
was signiﬁcantly higher in chronic Q fever patients than in controls, but with overlapping values between patients and seropositives.
Secondly, the production of a series of other cytokines was measured in a subset of patients and controls, which showed that interleukin
(IL)-2 production was signiﬁcantly lower in patients than in seropositive controls. Subsequently, measuring IL-2 in all patients and all controls
with substantial IFN-c production showed that an IFN-c/IL-2 ratio >11 had a sensitivity and speciﬁcity of 79% and 96%, respectively, to
diagnose chronic Q fever. This indicates that a high IFN-c/IL-2 ratio is highly suggestive for chronic Q fever. In an additional group of 25
individuals with persistent high anti-Coxiella phase I IgG titres without deﬁnite chronic infection, all but six showed an IFN-c/IL-2 ratio <11. In
conclusion, these ﬁndings hold promise for the often difﬁcult diagnostic work-up of Q fever and the IFN-c/IL-2 ratio may be used as an
additional diagnostic marker.
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Introduction
Q fever is caused by the intracellular bacterium Coxiella burnetii.
Some 1–5% of the infected individuals present with Q fever
endocarditis or infection of an aneurysm or vascular prosthesis
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(‘chronicQ fever’), months to years after primary infection [1,2].
If left untreated, these conditions are often fatal. Timely
diagnosis is therefore warranted, and treatment should be
started before irreversible damage has occurred. However,
diagnosis of Q fever endocarditis or vascular infection is not
easy, as culture is cumbersome and speciﬁc polymerase-chain
reaction (PCR) lacks sensitivity [3,4]. To date, serology is a key
factor in early detection of persistent infection, based on
measurement of antibodies against the two antigenic forms of
C. burnetii, phase I and II organisms, with high phase I anti-C. bur-
netii IgG titres (in the absence of acute Q fever) indicative
for chronic Q fever [5]. The appropriate cut-off titre that
differentiates it from a past cleared infection is debated; the
currently proposed cut-offs 1:1024 or 1:1600 have low
speciﬁcity [5–7].
Appropriate cytokine production is pivotal for the cellular
defence against the intracellular bacterium C. burnetii [8, 9], with
interferon-c (IFN-c), derived from T-cells and NK-cells, stim-
ulating macrophage microbicidal activity [10]. IFN-c is under the
control of type I interferons and interleukin-12 (IL-12), IL-18
and IL-23 [11]. Other cytokines also play a role: in Q fever
endocarditis, up-regulation of monocyte-derived tumour
necrosis factor-a (TNF-a), IL-1b and IL-6 from patients has
been reported [12], as well as overproduction of IL-10 [13,14].
Benoit et al. showed that C. burnetii induces M2 polarization of
macrophages in vitro with up-regulation of IL-1Receptor antag-
onist (IL-1Ra) and IL-6, and down-regulation of TNF-a [15]. In
the adaptive immune response to C. burnetii, cytokines such as
IL-2, stimulating lymphocyte proliferation and development of
memory responses [16], could also be important.
We recently showed that measurement of the cellular
immune response (i.e. in-vitro C. burnetii-speciﬁc IFN-c produc-
tion in whole blood) identiﬁes individuals who have been
previously exposed to C. burnetii [17]. In the present study, we
assessed the production of IFN-c, in combination with other
cytokines mentioned above, in patients with chronic Q fever,
with the aim of identifying a cytokine proﬁle that may aid in the
timely diagnosis of Q fever endocarditis or vascular infection.
Materials and Methods
Ethics statement
The study was approved by the Medical Ethical Committee
Arnhem-Nijmegen and written informed consent was obtained
from all subjects.
Study population
Twenty-eight Q fever endocarditis or vascular patients were
recruited from participating hospitals. At the time of diagnosis,
all patients had phase I IgG titres ≥1:1024 (in the absence of
acute Q fever), with either a positive C. burnetii PCR in serum
(n = 9) or tissue (n = 8) or both (n = 3) and/or signs of
endocarditis as deﬁned by the modiﬁed Duke criteria, or
undisputable evidence of vascular (prosthetic) infection on
positron emission tomography/computed tomography (PET/
CT)-scan or ultrasound (n = 8). Nine were diagnosed with Q
fever endocarditis and 19 had a vascular (prosthesis) Q fever
infection. They fulﬁlled the criteria for ‘proven chronic Q
fever’ of the Dutch consensus group on chronic Q fever
diagnostics [18].
Individuals screened in the Dutch Q fever vaccination
campaign from January to April 2011, as previously described,
were used as controls [17]. They all had pre-existing valvular
or vascular risk factors for Q fever endocarditis or vascular
infection [19]. Control individuals were classiﬁed as seroneg-
ative if both serological testing and the Q-vax skin test (CSL,
Parkville, Australia) were negative (n = 908). Controls were
classiﬁed as seropositive when serological tests showed
anti-C. burnetii antibodies (phase I or II IgG ≥1:32) without
signs or symptoms of persistent Q fever infection, and without
a serological proﬁle suggesting chronic Q fever infection
(phase I IgG ≤1:512), more than 1 year after the Q fever
epidemic (n = 135).
In a second stage of our study, an additional group of 25
patients was included, in whom the diagnosis of chronic
C. burnetii infection was suspected based on serology, all having
persistent phase I IgG ≥1:1,024, but could not be conﬁrmed
with PCR, or deﬁnite valvular or vascular focus of infection on
echocardiography or PET/CT. Fourteen of them had pre-exist-
ing valvular or vascular risk factors.
Measurement of C.burnetii-speciﬁc antibodies and detection
of C. burnetii DNA
IgG-antibodies against C. burnetii phase I and phase II were
measured by a commercially available immunoﬂuorescence
assay (IFA; Focus Diagnostics, Cypress, CA, USA).
Coxiella burnetii DNA in blood (serum/plasma) and tissue
was obtained using real-time PCR targeting the IS1111a
insertion element [20].
In-vitro whole blood stimulation
Cytokine production was measured in whole blood stimula-
tion, based on previous ﬁndings [17]. Venous blood was drawn
into 5-mL endotoxin-free lithium-heparin tubes (Vacutainer,
BD Biosciences) and samples were processed within 12 h.
Incubation was performed as previously described [17].
Coxiella burnetii Nine Mile (NM) RSA 493 phase I [21] was
used as well as Q-vax vaccine, containing formaldehyde-inac-
tivated C. burnetii Henzerling strain phase I. The mitogen
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phytohaemagglutinin (PHA, Sigma-Aldrich, St Louis, MO, USA)
was used as positive control. One aliquot was incubated with
only culture medium as negative control. After incubation,
blood cultures were centrifuged at 4656 g for 10 min and
supernatants were stored at 20°C until assayed.
Cytokine measurements
IFN-c concentration was measured in all samples, using a
commercial enzyme-linked immunosorbent assay (ELISA; Pel-
ikine compact, Sanquin, Amsterdam, the Netherlands) as
previously described [17].
To ﬁnd out if other cytokines would improve the discrim-
ination between patients and controls, a series of other
cytokines was measured in a subset of patients and samples:
TNF-a, IL-1b, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-10 were
measured using a multiplex beads assay (Merck Millipore,
Billerica, MA, USA). IL-12p70, IL-23 and IL-18 were measured
simultaneously in a magnetic beads multiplex assay (Merck
Millipore) according to the manufacturer’s instructions.
Statistical analysis
Graphpad Prism (Graphpad Software Inc., version 5) was used
to analyze the data. Cytokine results were displayed as
individual values or expressed as medians with interquartile
range. The Mann–Whitney U-test was used to determine
differences between groups. Spearman’s rho correlation
coefﬁcient was used to calculate correlation. Receiver oper-
ator characteristic (ROC) curves were constructed, and the
area under the curve (AUC) was assessed for the accuracy of
measuring (a ratio of) cytokine production. p <0.05 was
considered signiﬁcant.
Results
Patients and controls
From January 2011 until January 2012, blood samples were
obtained from 28 patients with Q fever endocarditis or
vascular infection. Their mean age ( standard deviation) was
66.2 ( 11.8) years; 78.6% were male. At the time of blood
sampling, ten patients did not yet receive antibiotics. The
median duration of antibiotic therapy among patients on
treatment (n = 18) was 7.5 months (range 1–26 months).
Patient characteristics at the time of blood sampling are shown
in Table 1.
Of the control individuals, 908 individuals (aged
63.6  14.0, 61.6% male) were seronegative; 135 individuals
(aged 60.8  15.1, 77.8% male) were seropositive. None of
the seropositive controls had detectable IgM antibodies
without IgG, suggesting the absence of acute Q fever.
Interferon-gamma production in 24 h-stimulated whole blood
We measured the IFN-c production (stimulated–unstimulated)
in undiluted whole blood incubated for 24 h with PHA, Q-vax
TABLE 1. Characteristics of 28 patients with deﬁnite chronic Q fever
Number Sex Age (yr) Focus of infection
Phase I IgG
titrea,b (inverse)
Phase II IgG
titrea,b (inverse)
PCR serum/
plasmaa
Duration of antibiotic
treatment (months)a
1 Male 82 Prosthetic valve 8192 16384 Positive 0
2 Male 72 Vascular prosthesis 8192 32768 Positive 0
3 Female 55 Vascular prosthesis 16384 65536 Positive 0
4 Male 69 Valvular repair 16384 16384 Positive 0
5 Male 70 Vascular prosthesis 4096 8192 Negative 0
6 Male 68 Vascular prosthesis 1024 2048 Negative 0
7 Male 68 Vascular prosthesis 32768 16384 Negative 0
8 Male 30 Vascular prosthesis 131072 131072 Positive 0
9 Female 77 Prosthetic valve 32768 32768 Positive 0
10 Male 69 Vascular prosthesis 8192 8192 Negative 0
11 Male 86 Vascular prosthesis 16384 8192 Negative 1
12 Male 66 Prosthetic valve 131072 131072 Positive 1
13 Male 64 Aortic aneurysm 8192 8192 Negative 2
14 Male 58 Prosthetic valve 2048 4096 Negative 6
15 Male 72 Biovalve 2048 2048 Negative 7
16 Female 60 Aortic aneurysm 8192 8192 Negative 7
17 Male 47 Vascular prosthesis 32768 32768 Positive 7
18 Male 73 Vascular prosthesis 8192 8192 Negative 7
19 Female 65 Biovalve 8192 8192 Positive 8
20 Male 72 Vascular prosthesis 8192 4096 Negative 9
21 Male 83 Aortic aneurysm 2048 2048 Negative 13
22 Female 66 Vascular prosthesis 2048 2048 Negative 18
23 Male 58 Vascular prosthesis 8192 32768 Negative 18
24 Male 80 Prosthetic valve 1024 4096 Positive 20
25 Male 69 Aortic aneurysm 4096 4096 Negative 20
26 Male 68 Aortic aneurysm 1024 512 Negative 20
27 Female 56 Vascular prosthesis 2048 2048 Negative 24
28 Male 51 Prosthetic valve n.a.c n.a.c Negative 26
n.a., not available.
aAt the moment of blood sampling.
bAs measured with immunoﬂuorescence assay (IFA).
cNot available, complement ﬁxation test (CFT) IgG anti-phase I > 160 and anti-phase II >640.
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or C. burnetii-NM in all patients and all controls (Fig. 1).
Aspeciﬁc PHA-induced IFN-c production did not differ
between groups. In contrast, both C. burnetii-antigens induced
signiﬁcantly more speciﬁc IFN-c in patients (median 151 pg/mL
and 2486 pg/mL by Q-vax and C. burnetii-NM, respectively)
than in seropositive controls (3.0 pg/mL and 120 pg/mL)
(p <0.001) and seronegative controls (0.0 and 0.0 pg/mL)
(p <0.001). Of interest, longer incubation shows higher
mitogen-induced IFN-c production than C. burnetii-speciﬁc
production (data not shown). Apparently, the speciﬁc
response is more rapid than the mitogen response.
ROC curves for C. burnetii-induced IFN-c for patients vs.
seropositive controls showed an accuracy (AUC) of 0.8664
(95% CI, 0.7933–0.9395; p <0.0001) (Fig. 2a); Q-vax-stimu-
lated IFN-c production showed lower accuracy (0.8484; 95%
CI, 0.7639–0.9330; p <0.0001) (Figure S1). Therefore, further
analyses were performed only with C. burnetii-NM-stimulated
samples. There was a considerable overlap between IFN-c
production in seropositive controls and Q fever patients
(Fig. 2b). Choosing 500 pg/mL as the optimal cut-off, 75.0%
(21/28) of the patients and 17.8% (24/135) of the seropositive
individuals had a value above this cut-off.
Interestingly, the height of IgG anti-phase I antibody titre
was signiﬁcantly correlated with the amount of IFN-c pro-
duced. Spearman’s rho in the total of seropositive controls and
Q fever patients was 0.3069 (p <0.001).
Further analyses of IFN-c production did not show signif-
icant differences between untreated (n = 10) and treated
(n = 18) Q fever patients (p 0.11); duration of treatment (in
months) did not correlate with IFN-c production (p 0.37).
Cytokine proﬁles in 48-h C. burnetii Nine Mile-stimulated
diluted blood in a subset of patients and controls
To ﬁnd out whether measurement of one or more additional
cytokines would help to distinguish chronic Q fever from past
infection, both conditions showing high IFN-c production, we
measured the production of TNF-a, IL-1b, IL-1Ra, IL-4, IL-5,
IL-6, IL-10, IL-12p70, IL-23, IL-18 and IL-2. Because not all
cytokines were expected to be detectable in the ﬁrst 24 h,
48-h C. burnetii-NM-stimulated diluted blood samples were
used. Cytokine production in samples of 16 patients (obtained
in the ﬁrst 10 months of the study), 18 seropositive controls
with substantial (≥32 pg/mL) IFN-c production in 24 h and 18
seronegative controls with low IFN-c production, were
compared. The results for IFN-c, IL-2, IL-1b, TNF-a, IL-10
and IL-1Ra are shown as Figure S2 in the supporting
information. As expected, the median IFN-c production did
not differ signiﬁcantly between patients and the selected
seropositive individuals. Most interestingly, production of IL-2
was signiﬁcantly lower in patients (median 5.0 pg/mL) than in
these seropositive controls (median 39.5 pg/mL) (p <0.001).
The production of the monocyte-derived cytokines IL-1b
and TNF-a was high in both chronic Q fever patients and in
seropositive individuals, but not signiﬁcantly different (p 0.24
and p 0.16 for IL-1b and TNF-a, respectively). However, both
were signiﬁcantly higher than in seronegative controls. The
same pattern was seen for IL-6 (not shown).
The anti-inﬂammatory cytokine IL-10 production also did
not differ between patients and seropositive controls. How-
ever, patients had signiﬁcantly higher IL-10 production than
seronegative individuals (p <0.01). IL-1Ra did not differ
between groups.
The C. burnetii-NM-stimulated production of IL-4, IL-5, IL-18
and IL-23 remained below detection limit. IL-12p70 levels were
very low and did not discriminate.
IFN-c/IL-2 ratio for diagnosis of chronic Q fever
In previous subset, patients with chronic Q fever showed high
IFN-c and low IL-2 production, whereas seropositive controls
with high IFN-c production showed high IL-2.
Next, we assessed IL-2 production in all patients and all 102
seropositive controls with substantial IFN-c production
≥32 pg/mL. The IFN-c/IL-2 ratio was calculated for each
individual (Fig. 2d). The AUC of the ROC-curve for patients
vs. seropositive controls was 0.8873 (95% CI, 0.7983–0.9762;
p <0.0001) (Fig. 2c). In 22/28 (78.6%) patients, the ratio was
FIG. 1. Coxiella burnetii-induced IFN-c production is higher in patients
than in seropositive and seronegative controls. Net IFN-c production
(stimulated minus unstimulated) is shown after 24 h incubation of
whole blood with phytohaemagglutinin (PHA) or C. burnetii-speciﬁc
antigens (Q-vax and C.b.-NM). Median  IQR are shown. The Mann–
Whitney U-test was used to compare medians. C.b.-NM, C. burnetii
Nine Mile; ns = not signiﬁcant, ***p <0.001.
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above 11, compared with only 6/102 (5.9%) seropositive
controls with an IFN-c production ≥32 pg/mL and 6/135
(4.4%) of all seropositives. So, the number of high values in the
seropositive controls diminished by 75% (from 24 to 6) at
cut-off 11 for IFN-c/IL-2 ratio compared with the cut-off
500 pg/mL for IFN-c production alone (Fig. 2e).
The IFN-c/IL-2 ratio did not correlate with the duration of
antibiotic treatment in patients (p 0.44), neither was there a
signiﬁcant difference between treated and untreated patients
(p 0.55). However, patients with positive C. burnetii PCR in
serum or plasma at the moment of blood sampling (n = 10),
had a signiﬁcantly higher IFN-c/IL-2 ratio than those with
negative PCR (n = 18) (median IFN-c/IL-2 ratio of 92.9 and
15.9, respectively, p <0.01).
IFN-c/IL-2 ratio in individuals with high phase I IgG without
deﬁnite chronic Q fever
Subsequently, the IFN-c/IL-2 ratio was determined in the group
of 25 individuals (aged 63.7  13.9, 72.0% male) in whom
chronic Q fever was suspected based on persistent high IgG
anti-C. burnetii phase I ≥1:1024, but without deﬁnite diagnosis of
chronic C. burnetii infection based on PCR, echocardiography or
PET/CT-scan. The results are shown separately for those with
and those without pre-existing cardiovascular risk factors for
chronic infection (Fig. 3). All but six had an IFN-c/IL-2 ratio
below the cut-off. A high IFN-c/IL-2 ratio was found in 2/11
(18%) in the group without and 4/14 (29%) in the group with risk
factors. The details of these six patients are shown in Table 2.
Interestingly, patient 1, without pre-existing risk factors but
persistent high phase I IgG and a high IFN-c/IL-2 ratio of 39, was
a veterinarian with non-speciﬁc complaints and a newly
diagnosed cardiac murmur. Echocardiography and PET/CT-scan
were normal and PCR on serum negative. After discontinuation
of 1.5 years treatment with doxycycline and hydroxychloroq-
uine without decreasing antibody titres, titres rose again. It
cannot be excluded that this veterinarian experienced ongoing
exposure to C. burnetii. Patient 2, having no valvular or vascular
risk factors for chronic Q fever but persistent high phase I IgG
and IFN-g/IL-2 above the cut-off, was immunocompromised
(prednisone use after kidney transplantation). He was started
on antibiotics because of suspected mitral valve involvement
based on PET/CT, which was considered inconclusive for
endocarditis by the nuclear medicine physician and could not be
conﬁrmed by echocardiography. Likewise, patient 3 was treated
for suspected Q fever vascular infection; however, the PET/CT
was interpreted to be inconclusive because of diffuse uptake in
the recently inserted vascular prosthesis. Patients 5 and 6 had
cardiac predisposition but no evidence of persistent infection
based on PCR, echocardiography or PET/CT-scan. Both,
however, were started on long-term antibiotics because of
the high risk of Q fever endocarditis. Only patient 4 did not
receive antibiotics and had spontaneously decreasing phase I
IgG titre, which persisted at 1:512 without signs or symptoms of
chronic active infection.
Discussion
In the present study, we show that Q fever endocarditis or
vascular patients exhibit high in-vitro IFN-c production and low
IL-2 production, while individuals with a past infection showed
both high IFN-c and high IL-2 production. The production of
monocyte-derived pro-inﬂammatory cytokines IL-1b, TNF-a
and IL-6 was high in patients as well as in individuals with past
infection and did not discriminate. Similarly, anti-inﬂammatory
cytokines IL-10 and IL-1Ra were not signiﬁcantly different in Q
fever patients and individuals with a past infection. In this
population, the IFN-c/IL-2 production ratio >11 had a sensi-
tivity and speciﬁcity of 79% and 96%, respectively, to diagnose
chronic Q fever.
FIG. 2. IFN-c production discriminates between patients with chronic Q fever and seropositive controls, but the ratio of IFN-c and IL-2 production
discriminates better. (a) Receiver operator characteristics (ROC) curve of the Coxiella burnetii-NM-stimulated IFN-c production after 24 h in whole
blood of chronic Q fever patients vs seropositive controls. The area under the curve (AUC) is 0.8664 (95% CI, 0.7933–0.9395; p <0.0001). The
arrow indicates the optimal cut-off of IFN-c production (500 pg/mL) with best combination of sensitivity and speciﬁcity. (b) The individual IFN-c
production is shown for chronic Q fever patients (n = 28) and seropositive controls (n = 135), plotted against phase I IgG titres. Each dot indicates
one individual. The horizontal line indicates the cut-off at 500 pg/ml. The vertical line distinguishes patients (closed circles) from controls (open
circles). (c) ROC curve of the IFN-c/IL-2 ratio in Q fever patients vs seropositive controls. AUC is 0.8873 (95% CI, 0.7983–0.9762). The arrow
indicates the optimal cut-off of IFN-c/IL-2 ratio at 11. (d) The individual IFN-c/IL-2 ratio is shown for chronic Q fever patients (n = 28) and
seropositive controls with IFN-c production ≥32 pg/mL (n = 102), plotted against phase I IgG. Each dot indicates one individual. The horizontal line
indicates an IFN-c/IL-2 ratio cut-off at 11. The vertical line distinguishes patients (closed circles) from controls (open circles). (e) Comparison
between IFN-c alone and the ratio of IFN-c/IL-2 to identify patients. IFN-c plotted against IL-2 production shows patients (black dots) and
seropositive controls (open dots). All patients (n = 28) and all seropositive controls with IFN-c production ≥32 pg/mL (n = 102) were included. The
horizontal line indicates the cut-off of IFN-c at 500 pg/mL. The sloping line indicates the cut-off IFN-c/IL-2 ratio at 11.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 642–650
646 Clinical Microbiology and Infection, Volume 20 Number 7, July 2014 CMI
(a)
(b)
(c) (d)
(e)
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 642–650
CMI Schoffelen et al. IFN-c/IL-2 ratio to diagnose chronic Q fever 647
Interestingly, we found that Q fever endocarditis and
vascular patients display high C. burnetii-speciﬁc IFN-c pro-
duction in whole blood, while it is commonly assumed that
chronicity of Q fever infection is due to T-lymphocyte
unresponsiveness and impaired IFN-c production [22,23].
We show here that C. burnetii-speciﬁc IFN-c production in
these patients is even higher than in individuals with past
C. burnetii infection. We obtained the same results when
using isolated peripheral blood mononuclear cells from
chronic patients and controls (unpublished data). This is in
accordance with the ﬁndings of Limonard et al. [24] report-
ing higher numbers of IFN-c-positive cells in three chronic Q
fever patients compared with nine convalescent controls,
using a Coxiella ELISPOT assay. Apparently, this high IFN-c
production by peripheral blood cells is not sufﬁcient to
activate C. burnetii-infected monocytes/macrophages at the
site of infection, to such an extent that the infection is
cleared. We hypothesize that downstream of IFN-c, the
response to this cytokine is aberrant in patients with
persistent C. burnetii infection.
The measurement of the production of monocyte-derived
cytokines did not aid in differentiation between chronic active
Q fever patients and individuals previously exposed to
C. burnetii. Nevertheless, both groups had higher production
than naive controls. From this it can be concluded that
restimulation with C. burnetii in primed individuals leads to
enhanced production of cytokines by monocytes. With regard
to the production of anti-inﬂammatory cytokines in chronic Q
fever patients, only that of IL-10 was higher than in seroneg-
ative controls. This is in line with previous reports on patients
with Q fever endocarditis [13,14]. The latter studies also
reported low IL-10 in individuals with Q fever without chronic
evolution. IL-10 appeared to induce C. burnetii replication and
its neutralization inhibits bacterial replication in monocytes
from patients with Q fever endocarditis [25]. Thus, IL-10 may
be important in the development of chronic Q fever, but we
found that measurement of C. burnetii-speciﬁc IL-10 produc-
tion is not a useful diagnostic marker.
Our ﬁnding that IL-2 production was signiﬁcantly lower in
chronic Q fever patients than in seropositive controls may be
to do with the types of T cell involved in the C. burnetii-speciﬁc
TABLE 2. Characteristics of six individuals with high IFN-c/IL-2 ratio and persistent high phase I IgG without deﬁnite chronic Q
fever
Case number,
sex, age (yr)
Pre-existing valvular or
vascular risk factor(s)
Serology at ﬁrst
diagnosis of persistent
high phase I IgG
(phase I IgG/phase II
IgG; inverse)
Results of PET/CT scan and echocardio-
graphy
Long-term
(1.5–2 years)
antibiotic
treatment
Serology at
moment of
blood sampling
(phase I IgG/
phase II IgG;
inverse)
IFN-c/IL-2
ratio at
moment
of blood
sampling
1, Female, 41 None 1024/1024 PET/CT and echocardiography negative Yes 1024/1024 39
2, Male, 67a None 8192/8192 PET/CT suspect aspect located at mitral valve,
not conclusive for endocarditis; TEE negative
Yes 8192/8192 12
3, Male, 71 Prosthesis aorta; fem-fem
crossover bypass
16384/16384 PET/CT possible focus of infection at fem-fem
crossover bypass, not conclusive, could be
reactivity to operation; TEE negative
Yes 4096/4096 55
4, Male, 64 Prosthesis aorta 1024/4096 PET/CT negative No 512/1024 40
5, Male, 71 Mitral and tricuspidal valve
repair
4096/2048 Echocardiography negative Yes 4096/4096 19
6, Male, 37 Mechanical aortic valve
prosthesis
32768/16384 PET/CT and echocardiography negative Yes 4096/4096 63
PET/CT, positron emission tomography/computed tomography; TEE, transoesophageal echocardiography; IFN-c, interferon-gamma; IL-2, interleukin-2.
aThis patient was immunocompromised (prednisone use after kidney transplantation).
FIG. 3. The ratio of IFN-c and IL-2 production in individuals with high
phase I IgG, without deﬁnite chronic Q fever. These 25 individuals
were diagnosed with persistent phase I IgG ≥1:1024, but no deﬁnite
chronic Q fever based on PCR, echocardiography or PET/CT-scan.
Eleven had no pre-existing cardiovascular risk factors for chronic Q
fever, while the other 14 had pre-existing valvular or vascular defects.
The horizontal dotted line indicates the previous established cut-off
IFN-c/IL-2 ratio at 11.
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immune responses. In chronic infection, we assume that
increased numbers of circulating C. burnetii-speciﬁc effector T
cells produce IFN-c and low amounts of IL-2 upon activation.
In seropositive controls, it is probably the central memory T
cell that dominates and produces mainly IL-2 [26]. We showed
that the ratio of IFN-c to IL-2 production is more speciﬁc than
IFN-c production alone (96% vs 82%), and has a slightly higher
sensitivity (79% vs 75%) to distinguish patients from seropos-
itive controls. The relative high speciﬁcity of the IFN-c/IL-2
ratio suggests that seropositive individuals with a ratio above
the cut-off merit thorough follow-up for the progression to Q
fever endocarditis or vascular infection.
In tuberculosis, measurement of speciﬁc IL-2 production in
addition to IFN-c also helps to differentiate between active and
latent infection. Here too, a high speciﬁc IFN-c and low IL-2
production is found in active infection, and both high IFN-c and
high IL-2 production indicate latent tuberculosis [27,28]. A
shift from T cells secreting only IFN-c and IFN-c/IL-2 to T cells
secreting IFN-c/IL-2 and only IL-2 is reported during treatment
of active tuberculosis [29].
Ten of the 28 patients were not yet on antibiotic treatment
at the moment of blood sampling. The absence of a signiﬁcant
difference in cytokine proﬁle between untreated and treated
patients suggests that the cytokine proﬁle observed is not
affected by the use of antibiotics. Still, the IFN-c/IL-2 ratio
seems to be related to the load of C. burnetii, because patients
with positive PCR for C. burnetii DNA in serum or plasma have
a signiﬁcantly higher ratio than patients with negative PCR.
Longitudinal studies are needed to assess the applicability of
the IFN-c/IL-2 ratio in follow-up during treatment of patients
with chronic Q fever.
All 28 patients included in the ﬁrst part of the study to
evaluate the performance of cytokine(s) production measure-
ments, had deﬁnite Q fever endocarditis or vascular infection.
We subsequently performed the measurements of IFN-c/IL-2
in a group of 25 individuals with an uncertain diagnosis (i.e.
having high phase I IgG without deﬁnite diagnosis of chronic
C. burnetii infection based on clinical criteria, PCR or deﬁnite
focus of infection on diagnostic imaging). It shows the
difﬁculties in assessing the value of a new marker in a group
of patients with uncertain diagnosis, some of whom are highly
suspected of having chronic Q fever, but not fulﬁlling the
criteria for deﬁnite chronic Q fever, neither those of Raoult
et al. nor those of the Dutch consensus [18,30]. In the great
majority of these difﬁcult cases (19/25), the IFN-c/IL-2 ratio
was low. This may imply absence of chronic C. burnetii
infection or a more low-grade infection. In some, the diagnosis
remains unclear because PCR and imaging techniques may have
lacked sensitivity to make a deﬁnite diagnosis before long-term
antibiotic treatment was started.
In conclusion, we found that a high IFN-c/IL-2 ratio is highly
suggestive for chronic Q fever. This ﬁnding holds promise for
the often difﬁcult diagnostic work-up of Q fever patients and
may be used as an additional diagnostic marker.
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